AHCY and cancer: Treatment with 3-deazaadenosine (3-DA), a general methylation inhibitor that depletes SAM by blocking S-adenosylhomocysteine hydrolase (SAHH) activity, reduces m6A levels and dramatically suppresses the migration and invasion of cancer cells [129].